Marshall Financial Group LLC Raises Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Marshall Financial Group LLC boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.9% during the 4th quarter, Holdings Channel reports. The fund owned 1,996 shares of the company’s stock after buying an additional 112 shares during the period. Marshall Financial Group LLC’s holdings in IDEXX Laboratories were worth $825,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IDXX. KFG Wealth Management LLC raised its stake in IDEXX Laboratories by 10.0% in the fourth quarter. KFG Wealth Management LLC now owns 1,092 shares of the company’s stock worth $451,000 after buying an additional 99 shares in the last quarter. B.O.S.S. Retirement Advisors LLC purchased a new position in shares of IDEXX Laboratories in the 4th quarter valued at $1,686,000. Linden Thomas Advisory Services LLC raised its position in shares of IDEXX Laboratories by 2.3% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 7,436 shares of the company’s stock worth $3,074,000 after acquiring an additional 169 shares in the last quarter. Bennett Selby Investments LP purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth $203,000. Finally, Exchange Traded Concepts LLC boosted its position in IDEXX Laboratories by 11.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 1,799 shares of the company’s stock valued at $744,000 after purchasing an additional 187 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now directly owns 905 shares of the company’s stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $435.33 on Friday. The firm has a market capitalization of $35.65 billion, a PE ratio of 41.98, a price-to-earnings-growth ratio of 3.63 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The company’s fifty day moving average price is $423.74 and its 200-day moving average price is $456.35. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. During the same quarter in the previous year, the business earned $2.53 EPS. The company’s quarterly revenue was up 6.6% compared to the same quarter last year. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Barclays reduced their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. JPMorgan Chase & Co. lowered their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $523.86.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.